Cipla to receive potential investment from FIL Capital for its WOS

21 Jul 2015 Evaluate

Cipla has received an approval to accept a potential investment by FIL Capital Investments (Mauritius) II, or any of its affiliate in a wholly owned subsidiary (WOS) of the company (proposed to be incorporated) to whom Cipla will be divesting its consumer healthcare business on a going-concern basis.

The board of directors at their meeting held on July 20, 2015 has approved for the same. The approval is subject to execution of binding agreements, and the transaction will be subject to relevant regulatory approvals.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1510.95 19.55 (1.31%)
31-Dec-2025 14:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.50
Dr. Reddys Lab 1273.00
Cipla 1510.95
Zydus Lifesciences 914.50
Lupin 2113.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×